664 results on '"David Finkelstein"'
Search Results
2. Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor
- Author
-
Carolyn M Jablonowski, Waise Quarni, Shivendra Singh, Haiyan Tan, Dhanushka Hewa Bostanthirige, Hongjian Jin, Jie Fang, Ti-Cheng Chang, David Finkelstein, Ji-Hoon Cho, Dongli Hu, Vishwajeeth Pagala, Sadie Miki Sakurada, Shondra M Pruett-Miller, Ruoning Wang, Andrew Murphy, Kevin Freeman, Junmin Peng, Andrew M Davidoff, Gang Wu, and Jun Yang
- Subjects
JMJD6 ,GLS ,neuroblastoma ,splicing ,indisulam ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Dysregulated pre-mRNA splicing and metabolism are two hallmarks of MYC-driven cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and therapies is poorly understood. Here, we demonstrate that jumonji domain containing 6, arginine demethylase, and lysine hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven human neuroblastoma. JMJD6 cooperates with MYC in cellular transformation of murine neural crest cells by physically interacting with RNA binding proteins involved in pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two isoforms of glutaminase (GLS), namely kidney-type glutaminase (KGA) and glutaminase C (GAC), which are rate-limiting enzymes of glutaminolysis in the central carbon metabolism in neuroblastoma. Further, we show that JMJD6 is correlated with the anti-cancer activity of indisulam, a ‘molecular glue’ that degrades splicing factor RBM39, which complexes with JMJD6. The indisulam-mediated cancer cell killing is at least partly dependent on the glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a cancer-promoting metabolic program is associated with alternative pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven cancers.
- Published
- 2024
- Full Text
- View/download PDF
3. Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia
- Author
-
Chun Shik Park, Hiroki Yoshihara, Qingsong Gao, Chunxu Qu, Ilaria Iacobucci, Pankaj S. Ghate, Jon P. Connelly, Shondra M. Pruett-Miller, Ben Wagner, Camenzind G. Robinson, Ashutosh Mishra, Junmin Peng, Lei Yang, Zoran Rankovic, David Finkelstein, Selina Luger, Mark Litzow, Elisabeth M. Paietta, Nikhil Hebbar, M. Paulina Velasquez, and Charles G. Mullighan
- Subjects
CP: Cancer ,Biology (General) ,QH301-705.5 - Abstract
Summary: The bone marrow microenvironment (BME) drives drug resistance in acute lymphoblastic leukemia (ALL) through leukemic cell interactions with bone marrow (BM) niches, but the underlying mechanisms remain unclear. Here, we show that the interaction between ALL and mesenchymal stem cells (MSCs) through integrin β1 induces an epithelial-mesenchymal transition (EMT)-like program in MSC-adherent ALL cells, resulting in drug resistance and enhanced survival. Moreover, single-cell RNA sequencing analysis of ALL-MSC co-culture identifies a hybrid cluster of MSC-adherent ALL cells expressing both B-ALL and MSC signature genes, orchestrated by a WNT/β-catenin-mediated EMT-like program. Blockade of interaction between β-catenin and CREB binding protein impairs the survival and drug resistance of MSC-adherent ALL cells in vitro and results in a reduction in leukemic burden in vivo. Targeting of this WNT/β-catenin-mediated EMT-like program is a potential therapeutic approach to overcome cell extrinsically acquired drug resistance in ALL.
- Published
- 2023
- Full Text
- View/download PDF
4. Modulation of protease expression by the transcription factor Ptx1/PITX regulates protein quality control during aging
- Author
-
Jianqin Jiao, Michelle Curley, Flavia A. Graca, Maricela Robles-Murguia, Abbas Shirinifard, David Finkelstein, Beisi Xu, Yiping Fan, and Fabio Demontis
- Subjects
CP: Molecular biology ,CP: Cell biology ,Biology (General) ,QH301-705.5 - Abstract
Summary: Protein quality control is important for healthy aging and is dysregulated in age-related diseases. The autophagy-lysosome and ubiquitin-proteasome are key for proteostasis, but it remains largely unknown whether other proteolytic systems also contribute to maintain proteostasis during aging. Here, we find that expression of proteolytic enzymes (proteases/peptidases) distinct from the autophagy-lysosome and ubiquitin-proteasome systems declines during skeletal muscle aging in Drosophila. Age-dependent protease downregulation undermines proteostasis, as demonstrated by the increase in detergent-insoluble poly-ubiquitinated proteins and pathogenic huntingtin-polyQ levels in response to protease knockdown. Computational analyses identify the transcription factor Ptx1 (homologous to human PITX1/2/3) as a regulator of protease expression. Consistent with this model, Ptx1 protein levels increase with aging, and Ptx1 RNAi counteracts the age-associated downregulation of protease expression. Moreover, Ptx1 RNAi improves muscle protein quality control in a protease-dependent manner and extends lifespan. These findings indicate that proteases and their transcriptional modulator Ptx1 ensure proteostasis during aging.
- Published
- 2023
- Full Text
- View/download PDF
5. Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity
- Author
-
Casey G. Langdon, Katherine E. Gadek, Matthew R. Garcia, Myron K. Evans, Kristin B. Reed, Madeline Bush, Jason A. Hanna, Catherine J. Drummond, Matthew C. Maguire, Patrick J. Leavey, David Finkelstein, Hongjian Jin, Patrick A. Schreiner, Jerold E. Rehg, and Mark E. Hatley
- Subjects
Science - Abstract
PTEN copy number loss is found in 25% of fusion-negative rhabdomyosarcomas (FN-RMS). Here, the authors use a Hedgehog-driven FN-RMS mouse model to show that PTEN loss drives the expression of core transcription factor PAX7 and its transcriptional axis, which determines FN-RMS tumour identity.
- Published
- 2021
- Full Text
- View/download PDF
6. A large-scale transgenic RNAi screen identifies transcription factors that modulate myofiber size in Drosophila.
- Author
-
Flavia A Graca, Natalie Sheffield, Melissa Puppa, David Finkelstein, Liam C Hunt, and Fabio Demontis
- Subjects
Genetics ,QH426-470 - Abstract
Myofiber atrophy occurs with aging and in many diseases but the underlying mechanisms are incompletely understood. Here, we have used >1,100 muscle-targeted RNAi interventions to comprehensively assess the function of 447 transcription factors in the developmental growth of body wall skeletal muscles in Drosophila. This screen identifies new regulators of myofiber atrophy and hypertrophy, including the transcription factor Deaf1. Deaf1 RNAi increases myofiber size whereas Deaf1 overexpression induces atrophy. Consistent with its annotation as a Gsk3 phosphorylation substrate, Deaf1 and Gsk3 induce largely overlapping transcriptional changes that are opposed by Deaf1 RNAi. The top category of Deaf1-regulated genes consists of glycolytic enzymes, which are suppressed by Deaf1 and Gsk3 but are upregulated by Deaf1 RNAi. Similar to Deaf1 and Gsk3 overexpression, RNAi for glycolytic enzymes reduces myofiber growth. Altogether, this study defines the repertoire of transcription factors that regulate developmental myofiber growth and the role of Gsk3/Deaf1/glycolysis in this process.
- Published
- 2021
- Full Text
- View/download PDF
7. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML
- Author
-
Daelynn R. Buelow, Stanley B. Pounds, Yong‐Dong Wang, Lei Shi, Yongjin Li, David Finkelstein, Sheila Shurtleff, Geoffrey Neale, Hiroto Inaba, Raul C. Ribeiro, Reid Palumbo, Dominique Garrison, Shelley J. Orwick, James S. Blachly, Karl Kroll, John C. Byrd, Tanja A. Gruber, Jeffrey E. Rubnitz, and Sharyn D. Baker
- Subjects
Therapeutics. Pharmacology ,RM1-950 ,Public aspects of medicine ,RA1-1270 - Abstract
Fms‐like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations, common in pediatric acute myeloid leukemia (AML), associate with early relapse and poor prognosis. Past studies have suggested additional cooperative mutations are required for leukemogenesis in FLT3‐ITD+ AML. Using RNA sequencing and a next‐generation targeted gene panel, we broadly characterize the co‐occurring genomic alterations in pediatric cytogenetically normal (CN) FLT3‐ITD+ AML to gain a deeper understanding of the clonal patterns and heterogeneity at diagnosis and relapse. We show that chimeric transcripts were present in 21 of 34 (62%) of de novo samples, 2 (6%) of these samples included a rare reoccurring fusion partner BCL11B. At diagnosis, the median number of mutations other than FLT3 per patient was 1 (range 0–3), which involved 8 gene pathways; WT1 and NPM1 mutations were frequently observed (35% and 24%, respectively). Fusion transcripts and high variant allele frequency (VAF) mutants, which included WT1, NPM1, SMARCA2, RAD21, and TYK2, were retained from diagnosis to relapse. We did observe reduction in VAF of simple or single mutation clones, but VAFs were preserved or expanded in more complex clones with multiple mutations. Our data provide the first insight into the genomic complexity of pediatric CN FLT3‐ITD+ AML and could help stratify future targeted treatment strategies.
- Published
- 2019
- Full Text
- View/download PDF
8. MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
- Author
-
Ida Annunziata, Diantha van de Vlekkert, Elmar Wolf, David Finkelstein, Geoffrey Neale, Eda Machado, Rosario Mosca, Yvan Campos, Heather Tillman, Martine F. Roussel, Jason Andrew Weesner, Leigh Ellen Fremuth, Xiaohui Qiu, Min-Joon Han, Gerard C. Grosveld, and Alessandra d’Azzo
- Subjects
Science - Abstract
Genes related to lysosomal and autophagic systems are transcriptionally regulated by the Mit/TFE family of transcription factors. Here the authors show that MYC, in association with HDACs, suppresses the expression of lysosomal and autophagy genes by competing with the Mit/TFE transcription factors for occupancy of their target gene promoters.
- Published
- 2019
- Full Text
- View/download PDF
9. Tissue-specific alteration of gene expression and function by RU486 and the GeneSwitch system
- Author
-
Maricela Robles-Murguia, Liam C. Hunt, David Finkelstein, Yiping Fan, and Fabio Demontis
- Subjects
Geriatrics ,RC952-954.6 - Abstract
Abstract The GeneSwitch (GS) is a modified Gal4/UAS system, whereby transgene expression is induced in Drosophila by adding the drug RU486 to food. The GS system is routinely used in Drosophila aging and behavioral studies to avoid confounding effects related to genetic background mutations. Here, we report transcriptional and functional defects that are induced by RU486 in a stock- and tissue-dependent manner, such as defects in flight and mitochondrial gene expression. In addition to including proper controls, our findings suggest that context-specific side effects induced by RU486 should be considered in the experimental design and when interpreting the observed phenotypes.
- Published
- 2019
- Full Text
- View/download PDF
10. Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail
- Author
-
Brandon R Lowe, Rajesh K Yadav, Ryan A Henry, Patrick Schreiner, Atsushi Matsuda, Alfonso G Fernandez, David Finkelstein, Margaret Campbell, Satish Kallappagoudar, Carolyn M Jablonowski, Andrew J Andrews, Yasushi Hiraoka, and Janet F Partridge
- Subjects
chromatin ,histone mutation ,cancer ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Sequencing of cancer genomes has identified recurrent somatic mutations in histones, termed oncohistones, which are frequently poorly understood. Previously we showed that fission yeast expressing only the H3.3G34R mutant identified in aggressive pediatric glioma had reduced H3K36 trimethylation and acetylation, increased genomic instability and replicative stress, and defective homology-dependent DNA damage repair. Here we show that surprisingly distinct phenotypes result from G34V (also in glioma) and G34W (giant cell tumors of bone) mutations, differentially affecting H3K36 modifications, subtelomeric silencing, genomic stability; sensitivity to irradiation, alkylating agents, and hydroxyurea; and influencing DNA repair. In cancer, only 1 of 30 alleles encoding H3 is mutated. Whilst co-expression of wild-type H3 rescues most G34 mutant phenotypes, G34R causes dominant hydroxyurea sensitivity, homologous recombination defects, and dominant subtelomeric silencing. Together, these studies demonstrate the complexity associated with different substitutions at even a single residue in H3 and highlight the utility of genetically tractable systems for their analysis.
- Published
- 2021
- Full Text
- View/download PDF
11. Metabolomic and transcriptomic analysis reveals endogenous substrates and metabolic adaptation in rats lacking Abcg2 and Abcb1a transporters.
- Author
-
Samit Ganguly, David Finkelstein, Timothy I Shaw, Ryan D Michalek, Kimberly M Zorn, Sean Ekins, Kazuto Yasuda, Yu Fukuda, John D Schuetz, Kamalika Mukherjee, and Erin G Schuetz
- Subjects
Medicine ,Science - Abstract
Abcg2/Bcrp and Abcb1a/Pgp are xenobiotic efflux transporters limiting substrate permeability in the gastrointestinal system and brain, and increasing renal and hepatic drug clearance. The systemic impact of Bcrp and Pgp ablation on metabolic homeostasis of endogenous substrates is incompletely understood. We performed untargeted metabolomics of cerebrospinal fluid (CSF) and plasma, transcriptomics of brain, liver and kidney from male Sprague Dawley rats (WT) and Bcrp/Pgp double knock-out (dKO) rats, and integrated metabolomic/transcriptomic analysis to identify putative substrates and perturbations in canonical metabolic pathways. A predictive Bayesian machine learning model was used to predict in silico those metabolites with greater substrate-like features for either transporters. The CSF and plasma levels of 169 metabolites, nutrients, signaling molecules, antioxidants and lipids were significantly altered in dKO rats, compared to WT rats. These metabolite changes suggested alterations in histidine, branched chain amino acid, purine and pyrimidine metabolism in the dKO rats. Levels of methylated and sulfated metabolites and some primary bile acids were increased in dKO CSF or plasma. Elevated uric acid levels appeared to be a primary driver of changes in purine and pyrimidine biosynthesis. Alterations in Bcrp/Pgp dKO CSF levels of antioxidants, precursors of neurotransmitters, and uric acid suggests the transporters may contribute to the regulation of a healthy central nervous system in rats. Microbiome-generated metabolites were found to be elevated in dKO rat plasma and CSF. The altered dKO metabolome appeared to cause compensatory transcriptional change in urate biosynthesis and response to lipopolysaccharide in brain, oxidation-reduction processes and response to oxidative stress and porphyrin biosynthesis in kidney, and circadian rhythm genes in liver. These findings present insight into endogenous functions of Bcrp and Pgp, the impact that transporter substrates, inhibitors or polymorphisms may have on metabolism, how transporter inhibition could rewire drug sensitivity indirectly through metabolic changes, and identify functional Bcrp biomarkers.
- Published
- 2021
- Full Text
- View/download PDF
12. Dynamic metabolic reprogramming in dendritic cells: An early response to influenza infection that is essential for effector function.
- Author
-
Svetlana Rezinciuc, Lavanya Bezavada, Azadeh Bahadoran, Susu Duan, Ruoning Wang, Daniel Lopez-Ferrer, David Finkelstein, Maureen A McGargill, Douglas R Green, Ljiljana Pasa-Tolic, and Heather S Smallwood
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
Infection with the influenza virus triggers an innate immune response that initiates the adaptive response to halt viral replication and spread. However, the metabolic response fueling the molecular mechanisms underlying changes in innate immune cell homeostasis remain undefined. Although influenza increases parasitized cell metabolism, it does not productively replicate in dendritic cells. To dissect these mechanisms, we compared the metabolism of dendritic cells to that of those infected with active and inactive influenza A virus and those treated with toll-like receptor agonists. Using quantitative mass spectrometry, pulse chase substrate utilization assays and metabolic flux measurements, we found global metabolic changes in dendritic cells 17 hours post infection, including significant changes in carbon commitment via glycolysis and glutaminolysis, as well as mitochondrial respiration. Influenza infection of dendritic cells led to a metabolic phenotype distinct from that induced by TLR agonists, with significant resilience in terms of metabolic plasticity. We identified c-Myc as one transcription factor modulating this response. Restriction of c-Myc activity or mitochondrial substrates significantly changed the immune functions of dendritic cells, such as reducing motility and T cell activation. Transcriptome analysis of inflammatory dendritic cells isolated following influenza infection showed similar metabolic reprogramming occurs in vivo. Thus, early in the infection process, dendritic cells respond with global metabolic restructuring, that is present in inflammatory lung dendritic cells after infection, and this is important for effector function. These findings suggest metabolic switching in dendritic cells plays a vital role in initiating the immune response to influenza infection.
- Published
- 2020
- Full Text
- View/download PDF
13. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma
- Author
-
Jesus García-López, Kirby Wallace, Joel H. Otero, Rachelle Olsen, Yong-dong Wang, David Finkelstein, Brian L. Gudenas, Jerold E. Rehg, Paul Northcott, Andrew M. Davidoff, and Kevin W. Freeman
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: Loss of heterozygosity (LOH) at 1p36 occurs in multiple cancers, including neuroblastoma (NBL). MYCN amplification and 1p36 deletions tightly correlate with markers of tumor aggressiveness in NBL. Although distal 1p36 losses associate with single-copy MYCN tumors, larger deletions correlate with MYCN amplification, indicating two tumor suppressor regions in 1p36, only one of which facilitates MYCN oncogenesis. To better define this region, we genome-edited the syntenic 1p36 locus in primary mouse neural crest cells (NCCs), a putative NBL cell of origin. In in vitro cell transformation assays, we show that Chd5 loss confers most of the MYCN-independent tumor suppressor effects of 1p36 LOH. In contrast, MYCN-driven tumorigenesis selects for NCCs with Arid1a deletions from a pool of NCCs with randomly sized 1p36 deletions, establishing Arid1a as the MYCN-associated tumor suppressor. Our findings reveal that Arid1a loss collaborates with oncogenic MYCN and better define the tumor suppressor functions of 1p36 LOH in NBL. : Garcia-Lopez et al. present a mouse model of high-risk neuroblastoma that includes 1p36 loss and Mycn overexpression. This study substantiates previous predictions from NBL genetic studies, which proposed that two tumor suppressor regions exist in 1p36. It further demonstrates that Mycn overexpression selects for loss of Arid1a during tumorigenesis. Keywords: chromatin remodelers, 1p36 LOH, ARID1A, CHD5, high-risk neuroblastoma
- Published
- 2020
- Full Text
- View/download PDF
14. UMI-count modeling and differential expression analysis for single-cell RNA sequencing
- Author
-
Wenan Chen, Yan Li, John Easton, David Finkelstein, Gang Wu, and Xiang Chen
- Subjects
Unique molecular identifier ,Negative binomial ,Differential expression analysis ,Biology (General) ,QH301-705.5 ,Genetics ,QH426-470 - Abstract
Abstract Read counting and unique molecular identifier (UMI) counting are the principal gene expression quantification schemes used in single-cell RNA-sequencing (scRNA-seq) analysis. By using multiple scRNA-seq datasets, we reveal distinct distribution differences between these schemes and conclude that the negative binomial model is a good approximation for UMI counts, even in heterogeneous populations. We further propose a novel differential expression analysis algorithm based on a negative binomial model with independent dispersions in each group (NBID). Our results show that this properly controls the FDR and achieves better power for UMI counts when compared to other recently developed packages for scRNA-seq analysis.
- Published
- 2018
- Full Text
- View/download PDF
15. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma
- Author
-
BaoHan T. Vo, Chunliang Li, Marc A. Morgan, Ilan Theurillat, David Finkelstein, Shaela Wright, Judith Hyle, Stephanie M.C. Smith, Yiping Fan, Yong-Dong Wang, Gang Wu, Brent A. Orr, Paul A. Northcott, Ali Shilatifard, Charles J. Sherr, and Martine F. Roussel
- Subjects
group 3 medulloblastoma ,MYC ,polycomb-repressive complex 2 ,PRC2 ,enhancer of zeste homology 2 ,EZH2 ,suppressor of zeste 12 homolog ,SUZ12 ,growth factor independent 1 ,GFI1 ,histone H3 modification ,Hox genes ,epigenetic repression ,Biology (General) ,QH301-705.5 - Abstract
The most aggressive of four medulloblastoma (MB) subgroups are cMyc-driven group 3 (G3) tumors, some of which overexpress EZH2, the histone H3K27 mono-, di-, and trimethylase of polycomb-repressive complex 2. Ezh2 has a context-dependent role in different cancers as an oncogene or tumor suppressor and retards tumor progression in a mouse model of G3 MB. Engineered deletions of Ezh2 in G3 MBs by gene editing nucleases accelerated tumorigenesis, whereas Ezh2 re-expression reversed attendant histone modifications and slowed tumor progression. Candidate oncogenic drivers suppressed by Ezh2 included Gfi1, a proto-oncogene frequently activated in human G3 MBs. Gfi1 disruption antagonized the tumor-promoting effects of Ezh2 loss; conversely, Gfi1 overexpression collaborated with Myc to bypass effects of Trp53 inactivation in driving MB progression in primary cerebellar neuronal progenitors. Although negative regulation of Gfi1 by Ezh2 may restrain MB development, Gfi1 activation can bypass these effects.
- Published
- 2017
- Full Text
- View/download PDF
16. A Key Role for the Ubiquitin Ligase UBR4 in Myofiber Hypertrophy in Drosophila and Mice
- Author
-
Liam C. Hunt, Jared Stover, Benard Haugen, Timothy I. Shaw, Yuxin Li, Vishwajeeth R. Pagala, David Finkelstein, Elisabeth R. Barton, Yiping Fan, Myriam Labelle, Junmin Peng, and Fabio Demontis
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: Skeletal muscle cell (myofiber) atrophy is a detrimental component of aging and cancer that primarily results from muscle protein degradation via the proteasome and ubiquitin ligases. Transcriptional upregulation of some ubiquitin ligases contributes to myofiber atrophy, but little is known about the role that most other ubiquitin ligases play in this process. To address this question, we have used RNAi screening in Drosophila to identify the function of > 320 evolutionarily conserved ubiquitin ligases in myofiber size regulation in vivo. We find that whereas RNAi for some ubiquitin ligases induces myofiber atrophy, loss of others (including the N-end rule ubiquitin ligase UBR4) promotes hypertrophy. In Drosophila and mouse myofibers, loss of UBR4 induces hypertrophy via decreased ubiquitination and degradation of a core set of target proteins, including the HAT1/RBBP4/RBBP7 histone-binding complex. Together, this study defines the repertoire of ubiquitin ligases that regulate myofiber size and the role of UBR4 in myofiber hypertrophy. : Hunt et al. use the fruit fly Drosophila to identify ubiquitin-related enzymes that regulate skeletal muscle cell (myofiber) size, including the ubiquitin ligase UBR4. Loss of UBR4 promotes myofiber hypertrophy in Drosophila and mice via decreased ubiquitination and degradation of a core set of target proteins. Keywords: ubiquitin ligase, skeletal muscle growth, myofiber hypertrophy, muscle wasting, cancer cachexia, UBR4, Drosophila, myofiber size, HAT1, proteolysis
- Published
- 2019
- Full Text
- View/download PDF
17. The Laminin-α1 Chain-Derived Peptide, AG73, Binds to Syndecans on MDA-231 Breast Cancer Cells and Alters Filopodium Formation
- Author
-
Madhavi Puchalapalli, Liang Mu, Chevaunne Edwards, Benjamin Kaplan-Singer, Pearl Eni, Kiran Belani, David Finkelstein, Arpan Patel, Megan Sayyad, and Jennifer E. Koblinski
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Breast cancer is one of the most common forms of cancer affecting women in the United States, second only to skin cancers. Although treatments have been developed to combat primary breast cancer, metastasis remains a leading cause of death. An early step of metastasis is cancer cell invasion through the basement membrane. However, this process is not yet well understood. AG73, a synthetic laminin-α1 chain peptide, plays an important role in cell adhesion and has previously been linked to migration, invasion, and metastasis. Thus, we aimed to identify the binding partner of AG73 on breast cancer cells that could mediate cancer progression. We performed adhesion assays using MCF10A, T47D, SUM1315, and MDA-231 breast cell lines and found that AG73 binds to syndecans (Sdcs) 1, 2, and 4. This interaction was inhibited when we silenced Sdcs 1 and/or 4 in MDA-231 cells, indicating the importance of these receptors in this relationship. Through actin staining, we found that silencing of Sdc 1, 2, and 4 expression in MDA-231 cells exhibits a decrease in the length and number of filopodia bound to AG73. Expression of mouse Sdcs 1, 2, and 4 in MDA-231 cells provides rescue in filopodia, and overexpression of Sdcs 1 and 2 leads to increased filopodium length and number. Our findings demonstrate an intrinsic interaction between AG73 in the tumor environment and the Sdcs on breast cancer cells in supporting tumor cell adhesion and invasion through filopodia, an important step in cancer metastasis.
- Published
- 2019
- Full Text
- View/download PDF
18. Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
- Author
-
Robert E. Sealy, Barry Dayton, David Finkelstein, and Julia L. Hurwitz
- Subjects
vaccines ,protective immunity ,Microbiology ,QR1-502 - Abstract
The year 2021 marks the 40th anniversary since physicians recognized symptoms of the acquired immunodeficiency syndrome (AIDS), a disease that has since caused more than 30 million deaths worldwide. Despite the passing of four decades, there remains no licensed vaccine for the human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS. Despite the development of outstanding anti-retroviral drugs, there are currently more than one-half million deaths each year due to AIDS. Here, we revisit a conventional vaccine strategy used for protection against variable pathogens like HIV-1, which combines an array of diverse surface antigens. The strategy uses antibody recognition patterns to categorize viruses and their surface antigens into groups. Then a leader is assigned for each group and group leaders are formulated into vaccine cocktails. The group leaders are ‘natural mosaics’, because they share one or more epitope(s) with each of the other group members. We encourage the application of this conventional approach to HIV-1 vaccine design. We suggest that the partnering of an antibody-instructed envelope cocktail with new vaccine vectors will yield a successful vaccine in the HIV-1 field.
- Published
- 2021
- Full Text
- View/download PDF
19. Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation
- Author
-
Yasmine A. Valentin-Vega, Yong-Dong Wang, Matthew Parker, Deanna M. Patmore, Anderson Kanagaraj, Jennifer Moore, Michael Rusch, David Finkelstein, David W. Ellison, Richard J. Gilbertson, Jinghui Zhang, Hong Joo Kim, and J. Paul Taylor
- Subjects
Medicine ,Science - Abstract
Abstract DDX3X is a DEAD-box RNA helicase that has been implicated in multiple aspects of RNA metabolism including translation initiation and the assembly of stress granules (SGs). Recent genomic studies have reported recurrent DDX3X mutations in numerous tumors including medulloblastoma (MB), but the physiological impact of these mutations is poorly understood. Here we show that a consistent feature of MB-associated mutations is SG hyper-assembly and concomitant translation impairment. We used CLIP-seq to obtain a comprehensive assessment of DDX3X binding targets and ribosome profiling for high-resolution assessment of global translation. Surprisingly, mutant DDX3X expression caused broad inhibition of translation that impacted DDX3X targeted and non-targeted mRNAs alike. Assessment of translation efficiency with single-cell resolution revealed that SG hyper-assembly correlated precisely with impaired global translation. SG hyper-assembly and translation impairment driven by mutant DDX3X were rescued by a genetic approach that limited SG assembly and by deletion of the N-terminal low complexity domain within DDX3X. Thus, in addition to a primary defect at the level of translation initiation caused by DDX3X mutation, SG assembly itself contributes to global translation inhibition. This work provides mechanistic insights into the consequences of cancer-related DDX3X mutations, suggesting that globally reduced translation may provide a context-dependent survival advantage that must be considered as a possible contributor to tumorigenesis.
- Published
- 2016
- Full Text
- View/download PDF
20. High-resolution transcriptional dissection of in vivo Atoh1-mediated hair cell conversion in mature cochleae identifies Isl1 as a co-reprogramming factor.
- Author
-
Tetsuji Yamashita, Fei Zheng, David Finkelstein, Zoe Kellard, Robert Carter, Celeste D Rosencrance, Ken Sugino, John Easton, Charles Gawad, and Jian Zuo
- Subjects
Genetics ,QH426-470 - Abstract
In vivo direct conversion of differentiated cells holds promise for regenerative medicine; however, improving the conversion efficiency and producing functional target cells remain challenging. Ectopic Atoh1 expression in non-sensory supporting cells (SCs) in mouse cochleae induces their partial conversion to hair cells (HCs) at low efficiency. Here, we performed single-cell RNA sequencing of whole mouse sensory epithelia harvested at multiple time points after conditional overexpression of Atoh1. Pseudotemporal ordering revealed that converted HCs (cHCs) are present along a conversion continuum that correlates with both endogenous and exogenous Atoh1 expression. Bulk sequencing of isolated cell populations and single-cell qPCR confirmed 51 transcription factors, including Isl1, are differentially expressed among cHCs, SCs and HCs. In transgenic mice, co-overexpression of Atoh1 and Isl1 enhanced the HC conversion efficiency. Together, our study shows how high-resolution transcriptional profiling of direct cell conversion can identify co-reprogramming factors required for efficient conversion.
- Published
- 2018
- Full Text
- View/download PDF
21. Acute Lung Injury Results from Innate Sensing of Viruses by an ER Stress Pathway
- Author
-
Eike R. Hrincius, Swantje Liedmann, David Finkelstein, Peter Vogel, Shane Gansebom, Amali E. Samarasinghe, Dahui You, Stephania A. Cormier, and Jonathan A. McCullers
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Incursions of new pathogenic viruses into humans from animal reservoirs are occurring with alarming frequency. The molecular underpinnings of immune recognition, host responses, and pathogenesis in this setting are poorly understood. We studied pandemic influenza viruses to determine the mechanism by which increasing glycosylation during evolution of surface proteins facilitates diminished pathogenicity in adapted viruses. ER stress during infection with poorly glycosylated pandemic strains activated the unfolded protein response, leading to inflammation, acute lung injury, and mortality. Seasonal strains or viruses engineered to mimic adapted viruses displaying excess glycans on the hemagglutinin did not cause ER stress, allowing preservation of the lungs and survival. We propose that ER stress resulting from recognition of non-adapted viruses is utilized to discriminate “non-self” at the level of protein processing and to activate immune responses, with unintended consequences on pathogenesis. Understanding this mechanism should improve strategies for treating acute lung injury from zoonotic viral infections.
- Published
- 2015
- Full Text
- View/download PDF
22. Casein Kinase 1δ Is an APC/CCdh1 Substrate that Regulates Cerebellar Granule Cell Neurogenesis
- Author
-
Clara Penas, Eve-Ellen Govek, Yin Fang, Vimal Ramachandran, Mark Daniel, Weiping Wang, Marie E. Maloof, Ronald J. Rahaim, Mathieu Bibian, Daisuke Kawauchi, David Finkelstein, Jeng-Liang Han, Jun Long, Bin Li, David J. Robbins, Marcos Malumbres, Martine F. Roussel, William R. Roush, Mary E. Hatten, and Nagi G. Ayad
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Although casein kinase 1δ (CK1δ) is at the center of multiple signaling pathways, its role in the expansion of CNS progenitor cells is unknown. Using mouse cerebellar granule cell progenitors (GCPs) as a model for brain neurogenesis, we demonstrate that the loss of CK1δ or treatment of GCPs with a highly selective small molecule inhibits GCP expansion. In contrast, CK1δ overexpression increases GCP proliferation. Thus, CK1δ appears to regulate GCP neurogenesis. CK1δ is targeted for proteolysis via the anaphase-promoting complex/cyclosome (APC/CCdh1) ubiquitin ligase, and conditional deletion of the APC/CCdh1 activator Cdh1 in cerebellar GCPs results in higher levels of CK1δ. APC/CCdh1 also downregulates CK1δ during cell-cycle exit. Therefore, we conclude that APC/CCdh1 controls CK1δ levels to balance proliferation and cell-cycle exit in the developing CNS. Similar studies in medulloblastoma cells showed that CK1δ holds promise as a therapeutic target.
- Published
- 2015
- Full Text
- View/download PDF
23. Histone H3G34R mutation causes replication stress, homologous recombination defects and genomic instability in S. pombe
- Author
-
Rajesh K Yadav, Carolyn M Jablonowski, Alfonso G Fernandez, Brandon R Lowe, Ryan A Henry, David Finkelstein, Kevin J Barnum, Alison L Pidoux, Yin-Ming Kuo, Jie Huang, Matthew J O’Connell, Andrew J Andrews, Arzu Onar-Thomas, Robin C Allshire, and Janet F Partridge
- Subjects
cancer ,chromatin ,homologous recombination ,H3K36 ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Recurrent somatic mutations of H3F3A in aggressive pediatric high-grade gliomas generate K27M or G34R/V mutant histone H3.3. H3.3-G34R/V mutants are common in tumors with mutations in p53 and ATRX, an H3.3-specific chromatin remodeler. To gain insight into the role of H3-G34R, we generated fission yeast that express only the mutant histone H3. H3-G34R specifically reduces H3K36 tri-methylation and H3K36 acetylation, and mutants show partial transcriptional overlap with set2 deletions. H3-G34R mutants exhibit genomic instability and increased replication stress, including slowed replication fork restart, although DNA replication checkpoints are functional. H3-G34R mutants are defective for DNA damage repair by homologous recombination (HR), and have altered HR protein dynamics in both damaged and untreated cells. These data suggest H3-G34R slows resolution of HR-mediated repair and that unresolved replication intermediates impair chromosome segregation. This analysis of H3-G34R mutant fission yeast provides mechanistic insight into how G34R mutation may promote genomic instability in glioma.
- Published
- 2017
- Full Text
- View/download PDF
24. Correction: Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline is Regulated by Different Cancer Stem Cell Populations.
- Author
-
Jo Meagan Garner, David W Ellison, David Finkelstein, Debolina Ganguly, Ziyun Du, Michelle Sims, Chuan He Yang, Rodrigo B Interiano, Andrew M Davidoff, and Lawrence M Pfeffer
- Subjects
Medicine ,Science - Abstract
[This corrects the article DOI: 10.1371/journal.pone.0125838.].
- Published
- 2015
- Full Text
- View/download PDF
25. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
- Author
-
Jo Meagan Garner, David W Ellison, David Finkelstein, Debolina Ganguly, Ziyun Du, Michelle Sims, Chuan He Yang, Rodrigo B Interiano, Andrew M Davidoff, and Lawrence M Pfeffer
- Subjects
Medicine ,Science - Abstract
Malignant glioblastoma (GBM) is a highly aggressive brain tumor with a dismal prognosis and limited therapeutic options. Genomic profiling of GBM samples has identified four molecular subtypes (Proneural, Neural, Classical and Mesenchymal), which may arise from different glioblastoma stem-like cell (GSC) populations. We previously showed that adherent cultures of GSCs grown on laminin-coated plates (Ad-GSCs) and spheroid cultures of GSCs (Sp-GSCs) had high expression of stem cell markers (CD133, Sox2 and Nestin), but low expression of differentiation markers (βIII-tubulin and glial fibrillary acid protein). In the present study, we characterized GBM tumors produced by subcutaneous and intracranial injection of Ad-GSCs and Sp-GSCs isolated from a patient-derived xenoline. Although they formed tumors with identical histological features, gene expression analysis revealed that xenografts of Sp-GSCs had a Classical molecular subtype similar to that of bulk tumor cells. In contrast xenografts of Ad-GSCs expressed a Mesenchymal gene signature. Adherent GSC-derived xenografts had high STAT3 and ANGPTL4 expression, and enrichment for stem cell markers, transcriptional networks and pro-angiogenic markers characteristic of the Mesenchymal subtype. Examination of clinical samples from GBM patients showed that STAT3 expression was directly correlated with ANGPTL4 expression, and that increased expression of these genes correlated with poor patient survival and performance. A pharmacological STAT3 inhibitor abrogated STAT3 binding to the ANGPTL4 promoter and exhibited anticancer activity in vivo. Therefore, Ad-GSCs and Sp-GSCs produced histologically identical tumors with different gene expression patterns, and a STAT3/ANGPTL4 pathway is identified in glioblastoma that may serve as a target for therapeutic intervention.
- Published
- 2015
- Full Text
- View/download PDF
26. Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica.
- Author
-
Jim Geiser, Robert C De Lisle, David Finkelstein, Paul A Adlard, Ashley I Bush, and Glen K Andrews
- Subjects
Medicine ,Science - Abstract
BackgroundZinc deficiency due to poor nutrition or genetic mutations in zinc transporters is a global health problem and approaches to providing effective dietary zinc supplementation while avoiding potential toxic side effects are needed.Methods/principal findingsConditional knockout of the intestinal zinc transporter Zip4 (Slc39a4) in mice creates a model of the lethal human genetic disease acrodermatitis enteropathica (AE). This knockout leads to acute zinc deficiency resulting in rapid weight loss, disrupted intestine integrity and eventually lethality, and therefore provides a model system in which to examine novel approaches to zinc supplementation. We examined the efficacy of dietary clioquinol (CQ), a well characterized zinc chelator/ionophore, in rescuing the Zip4 (intest KO) phenotype. By 8 days after initiation of the knockout neither dietary CQ nor zinc supplementation in the drinking water was found to be effective at improving this phenotype. In contrast, dietary CQ in conjunction with zinc supplementation was highly effective. Dietary CQ with zinc supplementation rapidly restored intestine stem cell division and differentiation of secretory and the absorptive cells. These changes were accompanied by rapid growth and dramatically increased longevity in the majority of mice, as well as the apparent restoration of the homeostasis of several essential metals in the liver.ConclusionsThese studies suggest that oral CQ (or other 8-hydroxyquinolines) coupled with zinc supplementation could provide a facile approach toward treating zinc deficiency in humans by stimulating stem cell proliferation and differentiation of intestinal epithelial cells.
- Published
- 2013
- Full Text
- View/download PDF
27. H5N1 Influenza Virus Pathogenesis in Genetically Diverse Mice Is Mediated at the Level of Viral Load
- Author
-
Adrianus C. M. Boon, David Finkelstein, Ming Zheng, Guochun Liao, John Allard, Klaus Klumpp, Robert Webster, Gary Peltz, and Richard J. Webby
- Subjects
Microbiology ,QR1-502 - Abstract
ABSTRACT The genotype of the host is one of several factors involved in the pathogenesis of an infectious disease and may be a key parameter in the epidemiology of highly pathogenic H5N1 influenza virus infection in humans. Gene polymorphisms may affect the viral replication rate or alter the host’s immune response to the virus. In humans, it is unclear which aspect dictates the severity of H5N1 virus disease. To identify the mechanism underlying differential responses to H5N1 virus infection in a genetically diverse population, we assessed the host responses and lung viral loads in 21 inbred mouse strains upon intranasal inoculation with A/Hong Kong/213/03 (H5N1). Resistant mouse strains survived large inocula while susceptible strains succumbed to infection with 1,000- to 10,000-fold-lower doses. Quantitative analysis of the viral load after inoculation with an intermediate dose found significant associations with lethality as early as 2 days postinoculation, earlier than any other disease indicator. The increased viral titers in the highly susceptible strains mediated a hyperinflamed environment, indicated by the distinct expression profiles and increased production of inflammatory mediators on day 3. Supporting the hypothesis that viral load rather than an inappropriate response to the virus was the key severity-determining factor, we performed quantitative real-time PCR measuring the cytokine/viral RNA ratio. No significant differences between susceptible and resistant mouse strains were detected, confirming that it is the host genetic component controlling viral load, and therefore replication dynamics, that is primarily responsible for a host’s susceptibility to a given H5N1 virus. IMPORTANCE Highly pathogenic H5N1 influenza virus has circulated in Southeast Asia since 2003 but has been confirmed in relatively few individuals. It has been postulated that host genetic polymorphisms increase the susceptibility to infection and severe disease. The mechanisms and host proteins affected during severe disease are unknown. Inbred mouse strains vary considerably in their ability to resist H5N1 virus and were used to identify the primary mechanism determining disease severity. After inoculation with H5N1, resistant mouse strains had reduced amounts of virus in their lungs, which subsequently resulted in lower production of proinflammatory mediators and less pathology. We therefore conclude that the host genetic component controlling disease severity is primarily influencing viral replication. This is an important concept, as it emphasizes the need to limit virus replication through antiviral therapies and it shows that the hyperinflammatory environment is simply a reflection of more viral genetic material inducing a response.
- Published
- 2011
- Full Text
- View/download PDF
28. Preclinical models for neuroblastoma: establishing a baseline for treatment.
- Author
-
Tal Teitz, Jennifer J Stanke, Sara Federico, Cori L Bradley, Rachel Brennan, Jiakun Zhang, Melissa D Johnson, Jan Sedlacik, Madoka Inoue, Ziwei M Zhang, Sharon Frase, Jerold E Rehg, Claudia M Hillenbrand, David Finkelstein, Christopher Calabrese, Michael A Dyer, and Jill M Lahti
- Subjects
Medicine ,Science - Abstract
Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time consuming surgery for orthotopic transplants and the absence of an intact immune system.Here we characterize and optimize both systems to increase their utility for preclinical studies. We show that TH-MYCN mice develop tumors in the paraspinal ganglia, but not in the adrenal, with cellular and gene expression patterns similar to human NB. In addition, we present a new ultrasound guided, minimally invasive orthotopic xenograft method. This injection technique is rapid, provides accurate targeting of the injected cells and leads to efficient engraftment. We also demonstrate that tumors can be detected, monitored and quantified prior to visualization using ultrasound, MRI and bioluminescence. Finally we develop and test a "standard of care" chemotherapy regimen. This protocol, which is based on current treatments for neuroblastoma, provides a baseline for comparison of new therapeutic agents.The studies suggest that use of both the TH-NMYC model of neuroblastoma and the orthotopic xenograft model provide the optimal combination for testing new chemotherapies for this devastating childhood cancer.
- Published
- 2011
- Full Text
- View/download PDF
29. Chapter One BUSINESS OF THE PRESS
- Author
-
Nicholas Brownlees and David Finkelstein
- Published
- 2023
- Full Text
- View/download PDF
30. Supplementary Data from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
- Author
-
Jinghui Zhang, James R. Downing, Keith Perry, Richard Daly, Michael Rusch, Scott Newman, Geralyn Miller, Michael A. Dyer, Suzanne J. Baker, Charles G. Mullighan, Chaitanya Bangur, David W. Ellison, Kim E. Nichols, Yutaka Yasui, Leslie L. Robison, Gregory T. Armstrong, Mitchell J. Weiss, Ludmil B. Alexandrov, Soheil Meshinchi, Yong Cheng, Carmen L. Wilson, Zhaoming Wang, Alberto S. Pappo, Matthew Lear, James McMurry, Leigh Tanner, Ed Suh, Gang Wu, Lance E. Palmer, Xing Tang, Darrell Gentry, Nedra Robison, Irina McGuire, Omar Serang, Tuan Nguyen, Singer Ma, Vijay Kandali, Pamella Tater, Naina Thangaraj, Christopher Meyer, S.M. Ashiqul Islam, Shaohua Lei, Liqing Tian, Ti-Cheng Chang, Andrew M. Frantz, Mark R. Wilkinson, Michael N. Edmonson, Aman Patel, Xiaotu Ma, Yu Liu, J. Robert Michael, Shuoguo Wang, Edgar Sioson, Jian Wang, Scott Foy, Stephanie Wiggins, Andrew Swistak, Arthur Chiao, Tracy K. Ard, Bob Davidson, Madison Treadway, Brent A. Orr, Rahul Mudunuri, Jobin Sunny, David Finkelstein, Kirby Birch, Michael Macias, Samuel W. Brady, Delaram Rahbarinia, Andrew Thrasher, Xin Zhou, Alexander M. Gout, and Clay McLeod
- Abstract
Involves Supplementary Table Legends and Supplementary Figures and associated legends
- Published
- 2023
- Full Text
- View/download PDF
31. Data from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
- Author
-
Jinghui Zhang, James R. Downing, Keith Perry, Richard Daly, Michael Rusch, Scott Newman, Geralyn Miller, Michael A. Dyer, Suzanne J. Baker, Charles G. Mullighan, Chaitanya Bangur, David W. Ellison, Kim E. Nichols, Yutaka Yasui, Leslie L. Robison, Gregory T. Armstrong, Mitchell J. Weiss, Ludmil B. Alexandrov, Soheil Meshinchi, Yong Cheng, Carmen L. Wilson, Zhaoming Wang, Alberto S. Pappo, Matthew Lear, James McMurry, Leigh Tanner, Ed Suh, Gang Wu, Lance E. Palmer, Xing Tang, Darrell Gentry, Nedra Robison, Irina McGuire, Omar Serang, Tuan Nguyen, Singer Ma, Vijay Kandali, Pamella Tater, Naina Thangaraj, Christopher Meyer, S.M. Ashiqul Islam, Shaohua Lei, Liqing Tian, Ti-Cheng Chang, Andrew M. Frantz, Mark R. Wilkinson, Michael N. Edmonson, Aman Patel, Xiaotu Ma, Yu Liu, J. Robert Michael, Shuoguo Wang, Edgar Sioson, Jian Wang, Scott Foy, Stephanie Wiggins, Andrew Swistak, Arthur Chiao, Tracy K. Ard, Bob Davidson, Madison Treadway, Brent A. Orr, Rahul Mudunuri, Jobin Sunny, David Finkelstein, Kirby Birch, Michael Macias, Samuel W. Brady, Delaram Rahbarinia, Andrew Thrasher, Xin Zhou, Alexander M. Gout, and Clay McLeod
- Abstract
Effective data sharing is key to accelerating research to improve diagnostic precision, treatment efficacy, and long-term survival in pediatric cancer and other childhood catastrophic diseases. We present St. Jude Cloud (https://www.stjude.cloud), a cloud-based data-sharing ecosystem for accessing, analyzing, and visualizing genomic data from >10,000 pediatric patients with cancer and long-term survivors, and >800 pediatric sickle cell patients. Harmonized genomic data totaling 1.25 petabytes are freely available, including 12,104 whole genomes, 7,697 whole exomes, and 2,202 transcriptomes. The resource is expanding rapidly, with regular data uploads from St. Jude's prospective clinical genomics programs. Three interconnected apps within the ecosystem—Genomics Platform, Pediatric Cancer Knowledgebase, and Visualization Community—enable simultaneously performing advanced data analysis in the cloud and enhancing the Pediatric Cancer knowledgebase. We demonstrate the value of the ecosystem through use cases that classify 135 pediatric cancer subtypes by gene expression profiling and map mutational signatures across 35 pediatric cancer subtypes.Significance:To advance research and treatment of pediatric cancer, we developed St. Jude Cloud, a data-sharing ecosystem for accessing >1.2 petabytes of raw genomic data from >10,000 pediatric patients and survivors, innovative analysis workflows, integrative multiomics visualizations, and a knowledgebase of published data contributed by the global pediatric cancer community.This article is highlighted in the In This Issue feature, p. 995
- Published
- 2023
- Full Text
- View/download PDF
32. Data from Ontogeny and Sorafenib Metabolism
- Author
-
Sharyn D. Baker, Hiroto Inaba, Jeffrey E. Rubnitz, Erin G. Schuetz, Amarjit S. Chaudhry, Alice Gibson, David Finkelstein, Lie Li, Justin L. Roberts, and Eric I. Zimmerman
- Abstract
Purpose: To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide.Experimental Design: Steady-state pharmacokinetic studies of sorafenib and metabolites were conducted in 30 children and young adults (17 males; median age, 9.5 years) receiving sorafenib 150 mg/m2 or 200 mg/m2 twice daily. Sorafenib metabolism was evaluated in vitro at 10 μmol/L using a panel of purified human cytochrome P450 (CYP) enzymes. Sorafenib metabolism and CYP3A4 expression was evaluated in 52 human liver samples from donors of ≤20 years old. The drug–drug interaction potential between sorafenib and azole antifungal agents was evaluated in vitro and in vivo.Results: No age-related differences in sorafenib apparent oral clearance were observed. Mean sorafenib N-oxide metabolite ratio was 0.27 ± 0.14. In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026). Of the CYPs evaluated, sorafenib was exclusively metabolized to sorafenib N-oxide by CYP3A4. A trend for increased N-oxide formation in boys was observed in liver samples, which correlated with CYP3A4 mRNA expression. Posaconazole and voriconazole potently inhibited sorafenib N-oxide formation in vitro, and reduced sorafenib N-oxide formation in 3 children given sorafenib concurrent with azoles.Conclusion: We have identified several factors affecting interpatient variability in sorafenib metabolism to the active N-oxide metabolite including age, sex, and concurrent treatment with azole antifungals. This knowledge may provide important considerations for the clinical use of sorafenib in children and possibly other kinase inhibitors undergoing CYP3A4-mediated metabolism. Clin Cancer Res; 18(20); 5788–95. ©2012 AACR.
- Published
- 2023
- Full Text
- View/download PDF
33. Supplementary Figure 1 from Ontogeny and Sorafenib Metabolism
- Author
-
Sharyn D. Baker, Hiroto Inaba, Jeffrey E. Rubnitz, Erin G. Schuetz, Amarjit S. Chaudhry, Alice Gibson, David Finkelstein, Lie Li, Justin L. Roberts, and Eric I. Zimmerman
- Abstract
PDF file, 57K, Steady-state sorafenib metabolite ratios as a function of sex.
- Published
- 2023
- Full Text
- View/download PDF
34. Supplementary Methods from Ontogeny and Sorafenib Metabolism
- Author
-
Sharyn D. Baker, Hiroto Inaba, Jeffrey E. Rubnitz, Erin G. Schuetz, Amarjit S. Chaudhry, Alice Gibson, David Finkelstein, Lie Li, Justin L. Roberts, and Eric I. Zimmerman
- Abstract
PDF file, 104K.
- Published
- 2023
- Full Text
- View/download PDF
35. Sup. Fig 6 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Pathology of DHA and ABT-263 treatment in mice
- Published
- 2023
- Full Text
- View/download PDF
36. Supplementary Fig. 1 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
- Author
-
Gerard P. Zambetti, Raul C. Ribeiro, Bonald C. Figueiredo, Alberto S. Pappo, John M. Hicks, David Finkelstein, Geoffrey Neale, Zhifa Liu, Stanley Pounds, John Kim Choi, Carlos Rodriguez-Galindo, and Emilia Modolo Pinto
- Abstract
Discriminating gap size (DGS) criterion shows a gap in the distribution of the expression of MHC class II expression in the IPACTR cohort. Each panel plots the rank of expression value in the cohort on the y-axis and the positive quantile transformation (PQT) value on the x-axis. Solid blue circles indicate adrenocortical carcinomas, open red circles indicate adrenocortical adenomas, and black X-marks indicate undetermined histology. In each plot, the gray rectangle highlights the large gap in the distribution that discriminates adenomas from carcinomas which was identified by the DGS criterion.
- Published
- 2023
- Full Text
- View/download PDF
37. Supplementary Figure 3 from Ontogeny and Sorafenib Metabolism
- Author
-
Sharyn D. Baker, Hiroto Inaba, Jeffrey E. Rubnitz, Erin G. Schuetz, Amarjit S. Chaudhry, Alice Gibson, David Finkelstein, Lie Li, Justin L. Roberts, and Eric I. Zimmerman
- Abstract
PDF file, 93K, Inhibition of CYP3A4-mediated sorafenib metabolism by azole compounds.
- Published
- 2023
- Full Text
- View/download PDF
38. Sup Figure Legends and Methods from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Methods and Figure Legends for Supplement
- Published
- 2023
- Full Text
- View/download PDF
39. Sup. Fig. 5 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Synergistic effect of Ph+ human cell lines to combined treatment with DHA and ABT-263
- Published
- 2023
- Full Text
- View/download PDF
40. Sup. Fig. 4 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
DHA represses MCL-1 in TKI-resistant BCR-ABLT315I B-ALL cells
- Published
- 2023
- Full Text
- View/download PDF
41. Supplementary Table 3 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
- Author
-
Gerard P. Zambetti, Raul C. Ribeiro, Bonald C. Figueiredo, Alberto S. Pappo, John M. Hicks, David Finkelstein, Geoffrey Neale, Zhifa Liu, Stanley Pounds, John Kim Choi, Carlos Rodriguez-Galindo, and Emilia Modolo Pinto
- Abstract
The Primary Antibodies Used for Immunohistochemistry Studies
- Published
- 2023
- Full Text
- View/download PDF
42. Data from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Purpose: BCR-ABL+ B-ALL leukemic cells are highly dependent on the expression of endogenous antiapoptotic MCL-1 to promote viability and are resistant to BH3-mimetic agents such as navitoclax (ABT-263) that target BCL-2, BCL-XL, and BCL-W. However, the survival of most normal blood cells and other cell types is also dependent on Mcl-1. Despite the requirement for MCL-1 in these cell types, initial reports of MCL-1–specific BH3-mimetics have not described any overt toxicities associated with single-agent use, but these agents are still early in clinical development. Therefore, we sought to identify approved drugs that could sensitize leukemic cells to ABT-263.Experimental Design: A screen identified dihydroartemisinin (DHA), a water-soluble metabolite of the antimalarial artemisinin. Using mouse and human leukemic cell lines, and primary patient-derived xenografts, the effect of DHA on survival was tested, and mechanistic studies were carried out to discover how DHA functions. We further tested in vitro and in vivo whether combining DHA with ABT-263 could enhance the response of leukemic cells to combination therapy.Results: DHA causes the downmodulation of MCL-1 expression by triggering a cellular stress response that represses translation. The repression of MCL-1 renders leukemic cells highly sensitive to synergistic cell death induced by ABT-263 in a mouse model of BCR-ABL+ B-ALL both in vitro and in vivo. Furthermore, DHA synergizes with ABT-263 in human Ph+ ALL cell lines, and primary patient-derived xenografts of Ph+ ALL in culture.Conclusions: Our findings suggest that combining DHA with ABT-263 can improve therapeutic response in BCR-ABL+ B-ALL. Clin Cancer Res; 23(24); 7558–68. ©2017 AACR.
- Published
- 2023
- Full Text
- View/download PDF
43. Sup Fig 1 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
MCL-1 is repressed by DHA and Ectopic MCL-1 expression renders BCR-ABL+ B-ALL cells resistant to DHA-induced killing
- Published
- 2023
- Full Text
- View/download PDF
44. Supplementary Data from Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1–Dependent Myeloid Cells
- Author
-
Peter J. Murray, Paul G. Thomas, Stacey Schultz-Cherry, Stephane Pelletier, David Finkelstein, Armita Bahrami, Leonie Zeitler, Marion Russier, Clifford S. Guy, Taylor L. Wilson, Jeremy Chase Crawford, E. Kaitlynn Allen, and Lee-Ann Van de Velde
- Abstract
Supplemental Figure file
- Published
- 2023
- Full Text
- View/download PDF
45. Supplementary Figure Legends from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
- Author
-
Gerard P. Zambetti, Raul C. Ribeiro, Bonald C. Figueiredo, Alberto S. Pappo, John M. Hicks, David Finkelstein, Geoffrey Neale, Zhifa Liu, Stanley Pounds, John Kim Choi, Carlos Rodriguez-Galindo, and Emilia Modolo Pinto
- Abstract
Supplementary Fig 1. Discriminating gap size (DGS) criterion shows a gap in the distribution of the expression of MHC class II expression in the IPACTR cohort. Supplementary Fig 2. Immunohistochemical analysis of CD3, CD4, and CD8 expression.
- Published
- 2023
- Full Text
- View/download PDF
46. Data from Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma
- Author
-
Mark E. Hatley, Jerold E. Rehg, David Finkelstein, Jonathan C. Go, Matthew R. Garcia, Catherine J. Drummond, and Jason A. Hanna
- Abstract
Angiosarcoma is an aggressive vascular sarcoma with an extremely poor prognosis. Because of the relative rarity of this disease, its molecular drivers and optimal treatment strategies are obscure. DICER1 is an RNase III endoribonuclease central to miRNA biogenesis, and germline DICER1 mutations result in a cancer predisposition syndrome, associated with an increased risk of many tumor types. Here, we show that biallelic Dicer1 deletion with aP2-Cre drives aggressive and metastatic angiosarcoma independent of other genetically engineered oncogenes or tumor suppressor loss. Angiosarcomas in aP2-Cre;Dicer1Flox/- mice histologically and genetically resemble human angiosarcoma. miR-23 target genes, including the oncogenes Ccnd1 as well as Adam19, Plau, and Wsb1 that promote invasiveness and metastasis, were enriched in mouse and human angiosarcoma. These studies illustrate that Dicer1 can function as a traditional loss-of-function tumor suppressor gene, and they provide a fully penetrant animal model for the study of angiosarcoma development and metastasis. Cancer Res; 77(22); 6109–18. ©2017 AACR.
- Published
- 2023
- Full Text
- View/download PDF
47. Supplementary Data from Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis
- Author
-
Myriam Labelle, David Finkelstein, Ana Maria Zaske, Abbas Shirinifard, Georgia Clayton, Cecile Garcin, Eleanor Baker, Hannah Breeze-Jones, Benjamin A. Minden-Birkenmaier, Ruishan Wang, Glendin Pano, and Jagadeesh Janjanam
- Abstract
Supplementary Materials and Methods; Supplementary Figures S1 to S8; Supplementary Figure S1. WISP2 inhibits WISP1-induced Col I linearization; Supplementary Figure S2. WISP2 is less abundant in tumors than in adjacent normal tissues and is an inhibitor of WISP1-induced tumor cell invasion though Col I; Supplementary Figure S3. The C-terminal domain of WISP1 drives WISP1-induced cell invasion through Col I but is dispensable for WISP1-Col I binding; Supplementary Figure S4. Wisp1 is expressed by tumor cells and cancer-associated fibroblast (CAF)-enriched stromal cells isolated from primary breast tumors; Supplementary Figure S5. WISP2 and WISP1DCT block TGFb1-induced cell invasion through Col I by acting as WISP1 antagonists; Supplementary Figure S6. WISP2 limits collagen linearization but does not affect total type I collagen levels in 4T1 breast tumors; Supplementary Figure S7. WISP2 limits collagen linearization in aggressive 4T1-Wisp1 tumors and inhibits breast cancer metastasis; Supplementary Figure S8. WISP1 promotes whereas WISP2 inhibits human breast cancer metastasis; Supplementary Tables S1 to S3; Supplementary Table S1. gBlock sequence for the generation of pCDH-EF1-Wisp2+CTT2A- puro from pCDH-EF1-Wisp2-T2A-puro; Supplementary Table S2. Primers used for cloning; Supplementary Table S3. gRNAs targeting Wisp1 and of non-targeting control gRNAs; Supplementary References
- Published
- 2023
- Full Text
- View/download PDF
48. Sup Fig. 3 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Loss of NOXA expression does not prevent DHA-induced repression of MCL-1.
- Published
- 2023
- Full Text
- View/download PDF
49. Supplementary Figure 5 from Ontogeny and Sorafenib Metabolism
- Author
-
Sharyn D. Baker, Hiroto Inaba, Jeffrey E. Rubnitz, Erin G. Schuetz, Amarjit S. Chaudhry, Alice Gibson, David Finkelstein, Lie Li, Justin L. Roberts, and Eric I. Zimmerman
- Abstract
PDF file, 63K, Age- and sex-dependent sorafenib glucuronide formation and correlation with UGT1A9 mRNA expression in human liver samples.
- Published
- 2023
- Full Text
- View/download PDF
50. Sup Fig. 7 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
- Author
-
Joseph T. Opferman, Charles G. Mullighan, David Finkelstein, John C. Panetta, Ewa Kaminska, Haiyan Xu, Xue Yang, Anisha Kothari, Michelle L. Churchman, Meghan E. Turnis, and Amit Budhraja
- Abstract
Densitometry Data for Immunoblots
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.